Stocks and Investing Stocks and Investing
Mon, June 26, 2023

Justin Zelin Maintained (SNDX) at Strong Buy with Increased Target to $35 on, Jun 26th, 2023


Published on 2024-10-28 04:30:42 - WOPRAI, Justin Zelin
  Print publication without navigation


Justin Zelin of BTIG, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy with Increased Target from $34 to $35 on, Jun 26th, 2023.

Justin has made no other calls on SNDX in the last 4 months.



There are 4 other peers that have a rating on SNDX. Out of the 4 peers that are also analyzing SNDX, 0 agree with Justin's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Justin


  • Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $31 on, Wednesday, May 10th, 2023
  • Edward White of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $36 on, Tuesday, May 9th, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $36 on, Tuesday, March 7th, 2023
  • Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $34 on, Wednesday, March 1st, 2023

Contributing Sources